Tevogen Bio Inc.
TVGN | NASDAQ
$5.66
-$0.39 (-6.45%)
At close: Oct 30, 2026, 3:59 PM ET
$5.90
+$0.24 (+4.24%)
After-hours:
Oct 30, 2026, 7:30 PM ET
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | 403.58K | 378.36K | n/a | n/a |
Gross Profit | n/a | -403.58K | -378.36K | n/a | n/a |
Operating Income | -26.14M | -53.56M | -8.84M | -953.08K | -4.62M |
Interest Income | n/a | n/a | n/a | 4.95M | n/a |
Pretax Income | -26.28M | -13.73M | -60.48M | 4.41M | -15.6M |
Net Income | -26.28M | -10.11M | -60.48M | 4.41M | -15.6M |
Selling & General & Admin | 15.03M | 22.13M | 4.06M | 953.08K | 1.66M |
Research & Development | 11.11M | 31.03M | 4.4M | n/a | 2.96M |
Other Expenses | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 26.14M | 53.16M | 8.46M | 953.08K | 4.62M |
Interest Expense | 195.62K | 184.04K | 256.03K | n/a | 598.5K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 26.14M | 53.56M | 8.84M | 953.08K | 4.62M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 3.32M | 2.93M | 3.31M | 2.4M | 958.67K |
Shares Outstanding (Diluted) | 3.32M | 2.93M | 3.31M | 2.4M | 958.67K |
EPS (Basic) | -8.08 | -4.68 | -0.02 | 1.83 | -16.50 |
EPS (Diluted) | -8.08 | -4.68 | -0.02 | 1.83 | -16.50 |
EBITDA | -25.57M | -13.14M | -58.89M | 4.64M | -14.99M |
EBIT | -26.08M | -13.54M | -59.27M | 4.41M | -15M |
Depreciation & Amortization | 509.2K | 403.58K | 378.36K | 230.82K | 9.38K |
Add to Watchlist
Select watchlists to add or remove TVGN